Maher Agha, MD
Internal Medicine · Charlotte, NCNPI 1093783474
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 855 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 855 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$2K
- Novo Nordisk AS$2K
- Lilly USA, LLC$1K
- AbbVie$1K
- Boehringer Ingelheim$895
- plus $7K from 48 others
Across 869 payments — averaging $1163.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$582K
- AbbVie$391K
- H. Lundbeck A S$22K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$17K
- Indivior Inc.$150
What the payments were for
- Travel & lodging$1,0926%
- Food & beverage$16,22793%
- Education$800%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,399 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 73 | $72,952 |
| OzempicSemaglutide | 42 | $50,817 |
| EliquisApixaban | 38 | $44,368 |
| FarxigaDapagliflozin Propanediol | 41 | $33,366 |
| MounjaroTirzepatide | 31 | $32,591 |
| RybelsusSemaglutide | 19 | $29,162 |
| JanuviaSitagliptin Phosphate | 26 | $27,748 |
| XareltoRivaroxaban | 13 | $15,076 |
| LinzessLinaclotide | 17 | $9,951 |
| Repatha SureclickEvolocumab | 16 | $9,776 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $8,432 |
| MydayisDextroamphetamine/Amphetamine | 13 | $4,333 |
| Clorazepate Dipotassium | 26 | $3,592 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $3,315 |
| KlonopinClonazepam | 12 | $3,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $895 | $81,38386 claims |
| Novo NordiskOzempic, Rybelsus | $2,342 | $79,98061 claims |
| PfizerEliquis | $618 | $44,36838 claims |
| AstraZenecaFarxiga | $2,206 | $33,36641 claims |
| Lilly USA, LLCMounjaro | $1,489 | $32,59131 claims |
| MerckJanuvia | $636 | $27,74826 claims |
| Johnson & JohnsonXarelto | $348 | $15,07613 claims |
| AbbVieLinzess | $1,484 | $9,95117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Charlotte
- Saad UsmaniCharlotte$551K
- Marc JohnsonCharlotte$342K
- Maithili ChitnavisCharlotte$267K
- Jonathan SchwartzCharlotte$193K
- Perry RoyCharlotte$135K
- Benjamin BrooksCharlotte$91K
- Mark SchwartzCharlotte$80K
- Thomas WalshCharlotte$64K
- Lisa BellanfonteCharlotte$45K
- Nirmish ShahDurham$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.